-
Signature
-
/s/ Dr. Francis P. McCormick
-
Issuer symbol
-
BBIO
-
Transactions as of
-
24 Jun 2025
-
Net transactions value
-
-$4,422,800
-
Form type
-
4
-
Filing time
-
26 Jun 2025, 17:08:05 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| MCCORMICK FRANK |
Director |
C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR., SUITE 250, PALO ALTO |
/s/ Dr. Francis P. McCormick |
26 Jun 2025 |
0001257809 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
BBIO |
Common Stock |
Sale |
$4,422,800 |
-100,000 |
-10% |
$44.23 |
879,979 |
24 Jun 2025 |
By the Francis P. McCormick Rev Trust U/A DTD 1/27/2017 |
F1, F2 |
| holding |
BBIO |
Common Stock |
|
|
|
|
|
83,275 |
24 Jun 2025 |
Direct |
|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: